Nasdaq · CIK 0001855175
CTNM Contineum Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 35 d ago. Close $13.38 on Oct 9, 2026, +46% from the 52-week low and -24% from the high.
Contineum Therapeutics, Inc. (CTNM) has 43 SEC Form 4 filings on file from 12 insiders, the latest filed on Sep 8, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 1 open-market sell worth $41k, net -$41k.
18 open-market trades have been scored at CTNM. The newest: Carmine N. Stengone (CEO and President) sold $41k of stock on Sep 8, 2026, filed Sep 8, 2026, scored 1 (weak), under a 10b5-1 plan. The largest of the 18 shown: Daniel S. Lorrain (Chief Scientific Officer) sold $130k on Feb 24, 2026, scored 6 (weak), under a 10b5-1 plan. 3 insiders sold within 14 days of each other around Mar 2, 2026.
CTNM closed at $13.38 on Oct 9, 2026, 46% above its 52-week low and 24% below its 52-week high.
1 Form 144 notice of planned sales is on file, the latest filed Nov 18, 2024.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Contineum Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 1Weak | Carmine N. Stengone CEO and President sell | $41k 2,500 shares | -13% | - | |
| 2Weak | Daniel S. Lorrain Chief Scientific Officer sell | $55k 4,170 shares | -3% | +259% from low-18% from high | |
| 2Weak | Daniel S. Lorrain Chief Scientific Officer sell | $55k 4,170 shares | -3% | +288% from low-18% from high | |
| 2Weak | Daniel S. Lorrain Chief Scientific Officer sell | $56k 4,170 shares | -3% | +295% from low-16% from high | |
| 22Weak | Tim Watkins CMO & Head of Development sell | $54k 3,611 shares | -100% | +351% from low-4% from high | |
| 18Weak | Daniel S. Lorrain Chief Scientific Officer sell | $63k 4,170 shares | -3% | +351% from low-4% from high | |
| 6Weak | Daniel S. Lorrain Chief Scientific Officer sell | $130k 8,124 shares | -5% | +369% from low-0% from high | |
| 25Weak | Carmine N. Stengone CEO and President sell | $114k 7,100 shares | -37% | +369% from low-0% from high | |
| 0Weak | Daniel S. Lorrain Chief Scientific Officer sell | $1,600 100 shares | -0% | +371% from low0% from high | |
| 0Weak | Daniel S. Lorrain Chief Scientific Officer sell | $6,400 400 shares | -0% | +349% from low-3% from high | |
| 5Weak | Carmine N. Stengone CEO and President sell | $6,400 400 shares | -3% | +349% from low-3% from high | |
| 17Weak | Daniel S. Lorrain Chief Scientific Officer sell | $62k 4,170 shares | -3% | +347% from low0% from high | |
| 22Weak | Tim Watkins CMO & Head of Development sell | $51k 3,611 shares | -100% | +324% from low0% from high | |
| 9Weak | Daniel S. Lorrain Chief Scientific Officer sell | $44k 4,170 shares | -3% | +194% from low-30% from high | |
| 10Weak | Daniel S. Lorrain Chief Scientific Officer sell | $51k 4,170 shares | -2% | +262% from low-16% from high | |
| 14Weak | Tim Watkins CMO & Head of Development sell | $44k 3,611 shares | -100% | +255% from low-18% from high | |
| 0Weak | Daniel S. Lorrain Chief Scientific Officer sell | $16k 1,010 shares | -1% | - | |
| 5Weak | Daniel S. Lorrain Chief Scientific Officer sell | $101k 6,190 shares | -4% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 18, 2024 | DANIEL LORRAIN Officer | 26,370 0.14% of outstanding | $454k | Nov 18, 2024 | none |
Transactions
The newest 50 of 76 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Carmine N. Stengone CEO and President | MOption exercise Class A Common Stock10b5-1 | +2,500 | $1.01 | $2,525 | 19,717 | 35 d ago |
| Sep 8, 2026 | Carmine N. Stengone CEO and President | SOpen-market sale Class A Common Stock10b5-1 | -2,500 | $16.46 | $41k | 17,217 | 35 d ago |
| Sep 8, 2026 | Carmine N. Stengone CEO and President | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,500 | $0.00 | $0 | 274,430 | 35 d ago |
| Jun 26, 2026 | Troy A. Ignelzi director | AGrant or award Stock Option (right to buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 26, 2026 |
| Jun 26, 2026 | Olivia C Ware director | AGrant or award Stock Option (right to buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 26, 2026 |
| Jun 26, 2026 | Lori Lyons-Williams director | AGrant or award Stock Option (right to buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 26, 2026 |
| Jun 26, 2026 | Todd R. Brady director | AGrant or award Stock Option (right to buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 26, 2026 |
| Jun 26, 2026 | Gines Diego Miralles director | AGrant or award Stock Option (right to buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 26, 2026 |
| Jun 26, 2026 | Sarah Boyce director | AGrant or award Stock Option (right to buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 26, 2026 |
| Jun 26, 2026 | Evert B. Schimmelpennink director | AGrant or award Stock Option (right to buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 26, 2026 |
| Jun 1, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -4,170 | $13.16 | $55k | 139,372 | Jun 1, 2026 |
| May 1, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -3,870 | $13.06 | $51k | 143,842 | May 1, 2026 |
| May 1, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -300 | $13.84 | $4,152 | 143,542 | May 1, 2026 |
| Apr 6, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -4,170 | $13.43 | $56k | 147,712 | Apr 6, 2026 |
| Mar 2, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -4,170 | $15.01 | $63k | 151,882 | Mar 2, 2026 |
| Mar 2, 2026 | Tim Watkins CMO & Head of Development | MOption exercise Class A Common Stock10b5-1 | +3,611 | $4.50 | $16k | 3,611 | Mar 2, 2026 |
| Mar 2, 2026 | Tim Watkins CMO & Head of Development | SOpen-market sale Class A Common Stock10b5-1 | -3,611 | $15.02 | $54k | 0 | Mar 2, 2026 |
| Mar 2, 2026 | Tim Watkins CMO & Head of Development | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,611 | $0.00 | $0 | 249,167 | Mar 2, 2026 |
| Feb 24, 2026 | Daniel S. Lorrain Chief Scientific Officer | MOption exercise Class A Common Stock10b5-1 | +4,300 | $1.01 | $4,343 | 160,352 | Feb 26, 2026 |
| Feb 24, 2026 | Carmine N. Stengone CEO and President | MOption exercise Class A Common Stock10b5-1 | +4,400 | $1.26 | $5,544 | 19,354 | Feb 26, 2026 |
| Feb 24, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -4,300 | $16.03 | $69k | 156,052 | Feb 26, 2026 |
| Feb 24, 2026 | Carmine N. Stengone CEO and President | SOpen-market sale Class A Common Stock10b5-1 | -4,400 | $16.02 | $70k | 14,954 | Feb 26, 2026 |
| Feb 25, 2026 | Daniel S. Lorrain Chief Scientific Officer | MOption exercise Class A Common Stock10b5-1 | +3,824 | $1.01 | $3,862 | 159,876 | Feb 26, 2026 |
| Feb 25, 2026 | Carmine N. Stengone CEO and President | MOption exercise Class A Common Stock10b5-1 | +2,700 | $1.26 | $3,402 | 17,654 | Feb 26, 2026 |
| Feb 25, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -3,824 | $16.01 | $61k | 156,052 | Feb 26, 2026 |
| Feb 25, 2026 | Carmine N. Stengone CEO and President | SOpen-market sale Class A Common Stock10b5-1 | -2,700 | $16.02 | $43k | 14,954 | Feb 26, 2026 |
| Feb 24, 2026 | Carmine N. Stengone CEO and President | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,400 | $0.00 | $0 | 123,617 | Feb 26, 2026 |
| Feb 25, 2026 | Carmine N. Stengone CEO and President | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,700 | $0.00 | $0 | 120,917 | Feb 26, 2026 |
| Feb 24, 2026 | Daniel S. Lorrain Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,300 | $0.00 | $0 | 71,130 | Feb 26, 2026 |
| Feb 25, 2026 | Daniel S. Lorrain Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,824 | $0.00 | $0 | 67,306 | Feb 26, 2026 |
| Feb 19, 2026 | Daniel S. Lorrain Chief Scientific Officer | MOption exercise Class A Common Stock10b5-1 | +100 | $1.01 | $101 | 156,152 | Feb 20, 2026 |
| Feb 19, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -100 | $16.00 | $1,600 | 156,052 | Feb 20, 2026 |
| Feb 19, 2026 | Daniel S. Lorrain Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -100 | $0.00 | $0 | 75,430 | Feb 20, 2026 |
| Feb 11, 2026 | Daniel S. Lorrain Chief Scientific Officer | MOption exercise Class A Common Stock10b5-1 | +400 | $1.01 | $404 | 156,452 | Feb 13, 2026 |
| Feb 11, 2026 | Carmine N. Stengone CEO and President | MOption exercise Class A Common Stock10b5-1 | +400 | $1.26 | $504 | 15,354 | Feb 13, 2026 |
| Feb 11, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -400 | $16.00 | $6,400 | 156,052 | Feb 13, 2026 |
| Feb 11, 2026 | Carmine N. Stengone CEO and President | SOpen-market sale Class A Common Stock10b5-1 | -400 | $16.00 | $6,400 | 14,954 | Feb 13, 2026 |
| Feb 11, 2026 | Carmine N. Stengone CEO and President | MOption exercise Stock Option (right to buy)derivative10b5-1 | -400 | $0.00 | $0 | 128,017 | Feb 13, 2026 |
| Feb 11, 2026 | Daniel S. Lorrain Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | -400 | $0.00 | $0 | 75,530 | Feb 13, 2026 |
| Feb 3, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -3,000 | $14.82 | $44k | 157,222 | Feb 5, 2026 |
| Feb 3, 2026 | Daniel S. Lorrain Chief Scientific Officer | SOpen-market sale Class A Common Stock10b5-1 | -1,170 | $15.25 | $18k | 156,052 | Feb 5, 2026 |
| Jan 30, 2026 | Daniel S. Lorrain Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +160,000 | $0.00 | $0 | 160,000 | Jan 30, 2026 |
| Jan 30, 2026 | Carmine N. Stengone CEO and President | AGrant or award Stock Option (right to buy)derivative | +445,000 | $0.00 | $0 | 445,000 | Jan 30, 2026 |
| Jan 30, 2026 | Peter T Slover Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +192,000 | $0.00 | $0 | 192,000 | Jan 30, 2026 |
| Jan 30, 2026 | John Stephen Healy General Counsel and Corp Sec | AGrant or award Stock Option (right to buy)derivative | +206,411 | $0.00 | $0 | 206,411 | Jan 30, 2026 |
| Jan 28, 2026 | Tim Watkins CMO & Head of Development | MOption exercise Class A Common Stock10b5-1 | +3,611 | $4.50 | $16k | 3,611 | Jan 30, 2026 |
| Jan 30, 2026 | Daniel S. Lorrain Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivativeindirect: By Spouse | +6,500 | $0.00 | $0 | 6,500 | Jan 30, 2026 |
| Jan 28, 2026 | Tim Watkins CMO & Head of Development | SOpen-market sale Class A Common Stock10b5-1 | -2,800 | $14.09 | $39k | 811 | Jan 30, 2026 |
| Jan 28, 2026 | Tim Watkins CMO & Head of Development | SOpen-market sale Class A Common Stock10b5-1 | -811 | $14.48 | $12k | 0 | Jan 30, 2026 |
| Jan 28, 2026 | Tim Watkins CMO & Head of Development | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,611 | $0.00 | $0 | 252,778 | Jan 30, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Sarah Boyceceo, president, officer, director
- Todd R. Bradydirector
- John Stephen HealyGeneral Counsel and Corp Sec
- Troy A. Ignelzicfo, officer, director
- Daniel S. LorrainChief Scientific Officer
- Lori Lyons-Williamsdirector
- Gines Diego Mirallesdirector, president, officer
- Evert B. Schimmelpenninkdirector, ceo, president, officer
- Peter T SloverChief Financial Officer
- Carmine N. StengoneCEO and President
- Olivia C Waredirector
- Tim WatkinsCMO & Head of Development
Questions about CTNM
Answered from the filings on this page, as of the latest one.
Are insiders buying CTNM?
As of Sep 8, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 1 open-market sell worth $41k by 1 insider at Contineum Therapeutics, Inc. in the last 90 days, net -$41k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade CTNM on the open market?
Carmine N. Stengone (CEO and President) sold $41k of CTNM on Sep 8, 2026 and filed the Form 4 on Sep 8, 2026. InsiderTell scored 1 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at Contineum Therapeutics, Inc.?
12 people have filed a Form 4 at Contineum Therapeutics, Inc., among them Sarah Boyce (CEO, president and director), Todd R. Brady (director), John Stephen Healy (General Counsel and Corp Sec). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.